Microcap Ledger CalciMedica, Inc. $CALC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 34,141,460 [10-Q 2026-08-11]
What the company doesAI summary of filing
CalciMedica is a clinical-stage biopharmaceutical company developing therapeutics that inhibit calcium release-activated calcium (CRAC) channels for serious illnesses driven by inflammatory and immunologic processes. The company's lead product candidate is Auxora, an intravenously formulated small-molecule CRAC channel inhibitor that has been evaluated in multiple Phase 2 clinical trials for acute pancreatitis, acute kidney injury with respiratory failure, asparaginase-induced pancreatic toxicity in pediatric patients, and severe COVID-19 pneumonia. The company is currently advancing a potential pivotal program in acute pancreatitis and developing CM5480, another CRAC channel inhibitor for pulmonary arterial hypertension, with an investigational new drug application anticipated in 2027. CalciMedica generates no product revenue and is in the clinical development stage. [10-K 2026-03-03]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$2.68M | −$9.48M | $18.62M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$29.56M | −$21.18M | $11.52M | [DEF 14A 2026-07-23] |
| FY ended Dec 2024 | — | −$13.70M | −$21.15M | $7.93M | [DEF 14A 2026-07-23] |
- Quarterly cash burn
- −$4.74M
- Cash runway Estimate
- ~11.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 13,481,917 | [10-Q 2024-11-13] |
| 2025-03-21 | 13,481,917 | [10-K 2025-03-27] |
| 2025-05-06 | 13,971,990 | [10-Q 2025-05-14] |
| 2025-08-06 | 13,972,177 | [10-Q 2025-08-12] |
| 2026-02-25 | 15,743,916 | [10-K/A 2026-04-30] |
| 2026-02-26 | 15,743,916 | [10-K 2026-03-03] |
| 2026-05-07 | 15,798,031 | [10-Q 2026-05-12] |
| 2026-08-05 | 34,141,460 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-07-24; declared effective 2026-07-31 [S-3 2026-07-24]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Other events |
| 2026-09-30 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-16 | 8-K | Other events |
| 2026-09-02 | 8-K | Other events |
| 2026-08-27 | 8-K | Charter, bylaws or fiscal year change |
| 2026-08-25 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-24 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-21 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-20 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
Alerts for $CALC
Email me when CalciMedica, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.